Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $152.00 price target for the company in a report on Monday, July 16th. Citigroup upped their price target on shares of Alexion Pharmaceuticals from $173.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, September 25th. Robert W. Baird set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 24th. Credit Suisse Group set a $156.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 29th. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $161.29.

NASDAQ:ALXN opened at $123.44 on Thursday. Alexion Pharmaceuticals has a 52 week low of $102.10 and a 52 week high of $140.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.74. The firm has a market cap of $28.37 billion, a P/E ratio of 23.92, a PEG ratio of 1.10 and a beta of 0.99.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business posted $1.44 EPS. The firm’s revenue was up 19.5% compared to the same quarter last year. Equities research analysts expect that Alexion Pharmaceuticals will post 6.82 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Hawaiian Bank bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $102,000. Advisory Services Network LLC raised its stake in Alexion Pharmaceuticals by 145.3% during the 2nd quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 523 shares during the period. Columbia Asset Management bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $138,000. Checchi Capital Advisers LLC bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $204,000. Finally, K.J. Harrison & Partners Inc bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $209,000. Institutional investors own 92.89% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

See Also: How Do Tariffs Affect Trade Balances?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.